Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12615001302549
Ethics application status
Approved
Date submitted
25/11/2015
Date registered
30/11/2015
Date last updated
16/06/2017
Type of registration
Prospectively registered
Titles & IDs
Public title
The influence of genetic variants on inosine-induced hyperuricaemia
Query!
Scientific title
The influence of genetic variants on inosine-induced hyperuricaemia in healthy adult volunteers
Query!
Secondary ID [1]
287990
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Gout
296871
0
Query!
Hyperuricaemia
296887
0
Query!
Condition category
Condition code
Musculoskeletal
297102
297102
0
0
Query!
Other muscular and skeletal disorders
Query!
Metabolic and Endocrine
297103
297103
0
0
Query!
Other metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Oral inosine 1.5g will be administered under direct observation on a single occasion to all participants. Participants will then be observed for three hours.
Query!
Intervention code [1]
293332
0
Treatment: Drugs
Query!
Comparator / control treatment
Comparison between individuals possessing at least one protective allele at the SLC2A9 SNP rs11942223 and those without the protective allele
Comparison between individuals possessing at least one ABCG2 141K variant and those without the 141K variant.
These alleles are determined by testing a blood sample.
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
296711
0
Change in serum urate concentration following a inosine challenge (blood test)
Query!
Assessment method [1]
296711
0
Query!
Timepoint [1]
296711
0
15 minutes, 30 minutes, 60 minutes, 120 minutes, and 180 minutes after ingestion
Query!
Secondary outcome [1]
319158
0
Change in fractional excretion of urate to 3 hours following a inosine challenge (blood and urine test)
Query!
Assessment method [1]
319158
0
Query!
Timepoint [1]
319158
0
Blood and urine tests will be taken at the following time points: 30 minutes, 60 minutes, 120 minutes, and 180 minutes after ingestion
Query!
Eligibility
Key inclusion criteria
a. Able to provide written informed consent
b. eGFR>60 mL/min/1.73 m2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
a. History of gout
b. History of kidney stones
c. History of diabetes mellitus
d. Diuretic use
e. Urine pH less than or equal to 5.0 (risk factor for uric acid urolithiasis)
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/02/2016
Query!
Actual
3/02/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
9/08/2016
Query!
Date of last data collection
Anticipated
Query!
Actual
31/08/2016
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
100
Query!
Recruitment outside Australia
Country [1]
7368
0
New Zealand
Query!
State/province [1]
7368
0
Auckland
Query!
Funding & Sponsors
Funding source category [1]
292454
0
Government body
Query!
Name [1]
292454
0
Health Research Council
Query!
Address [1]
292454
0
Level 3 - ProCARE Building, Grafton Mews, at 110 Stanley Street, Auckland 1010
Query!
Country [1]
292454
0
New Zealand
Query!
Primary sponsor type
University
Query!
Name
University of Auckland
Query!
Address
85 Park Rd
Grafton Auckland 1023
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
291152
0
None
Query!
Name [1]
291152
0
NA
Query!
Address [1]
291152
0
NA
Query!
Country [1]
291152
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
293914
0
Southern Health and Disability Ethics Committee
Query!
Ethics committee address [1]
293914
0
C/- MEDSAFE, Level 6, Deloitte House 10 Brandon Street PO Box 5013 Wellington 6011
Query!
Ethics committee country [1]
293914
0
New Zealand
Query!
Date submitted for ethics approval [1]
293914
0
04/12/2015
Query!
Approval date [1]
293914
0
21/12/2015
Query!
Ethics approval number [1]
293914
0
Query!
Summary
Brief summary
This intervention study is designed to to examine the influence of genetic variation on inosine-induced hyperuricaemia. The primary endpoint is change in serum urate over 180 minutes after inosine ingestion. Key secondary and exploratory endpoints are change in fractional excretion of urate. The key genes of interest are SLC2A9 (GLUT9) and ABCG2. However, other genes associated with purine synthesis and urate transport may also be examined in later exploratory analyses.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
61810
0
Prof Nicola Dalbeth
Query!
Address
61810
0
Room 502-201D Bone and Joint Research Group Department of Medicine Faculty of Medical and Health Sciences University of Auckland 85 Park Rd, Grafton, Auckland 1023
Query!
Country
61810
0
New Zealand
Query!
Phone
61810
0
+64 (0) 9 3737999 x82568
Query!
Fax
61810
0
+64 (0) 9 3737677
Query!
Email
61810
0
[email protected]
Query!
Contact person for public queries
Name
61811
0
Anne Horne
Query!
Address
61811
0
Bone and Joint Research Group
Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
85 Park Rd, Grafton, Auckland 1023
Query!
Country
61811
0
New Zealand
Query!
Phone
61811
0
+64 (0) 9 3737999 x89787
Query!
Fax
61811
0
+64 (0) 9 3737677
Query!
Email
61811
0
[email protected]
Query!
Contact person for scientific queries
Name
61812
0
Nicola Dalbeth
Query!
Address
61812
0
Bone and Joint Research Group
Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
85 Park Rd, Grafton, Auckland 1023
Query!
Country
61812
0
New Zealand
Query!
Phone
61812
0
+64 (0) 9 3737999 x82568
Query!
Fax
61812
0
+64 (0) 9 3737677
Query!
Email
61812
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Effect of body mass index on serum urate and renal uric acid handling responses to an oral inosine load: experimental intervention study in healthy volunteers.
2020
https://dx.doi.org/10.1186/s13075-020-02357-y
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF